Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

RecruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2028

Conditions

ALK-positive Non-small Cell Lung CancerReal World Study

Interventions

DRUG

Lorlatinib

lolatinib 100mg qd po

Trial Locations (1)

RECRUITING

Sichuan cancer hospital, Chengdu

All Listed Sponsors

lead

Sichuan Cancer Hospital and Research Institute

OTHER